Monopar Therapeutics (MNPR) Invested Capital (2016 - 2025)

Monopar Therapeutics has disclosed Invested Capital across 10 years of filings, most recently posting $137.8 million for Q4 2025.

• Invested Capital for Q4 2025 came in at $137.8 million, up 150.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $137.8 million (up 150.43% YoY), and the FY2025 annual result was $137.8 million, up 150.43% from the prior year.
• Invested Capital came in at $137.8 million for Q4 2025 at Monopar Therapeutics, down from $141.6 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $141.6 million in Q3 2025 to a low of $4.9 million in Q3 2024.
• The 5-year median for Invested Capital is $15.7 million (2022), against an average of $31.5 million.
• Across the five-year window, Invested Capital plunged 47.28% in 2023 and soared 2761.61% in 2025, its largest moves.
• Monopar Therapeutics' Invested Capital stood at $18.9 million in 2021, then sank by 46.73% to $10.1 million in 2022, then sank by 44.62% to $5.6 million in 2023, then surged by 884.95% to $55.0 million in 2024, then surged by 150.43% to $137.8 million in 2025.
• The last three Invested Capital figures came in at $137.8 million (Q4 2025), $141.6 million (Q3 2025), and $52.2 million (Q2 2025), per Business Quant data.